Find Faculty
Christopher E Walsh, MD, PhD
img_Christopher E Walsh
ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
Are you a patient?
View my
Provider Profile
Specialties
Internal Medicine, Hematology-Oncology, Cancer (Oncology)
Research
Dr. Walsh directs the Hemophilia Program in the Division of Hematology and Medical Oncology at Mount Sinai School of Medicine. His research focuses on gene therapy of blood diseases. Throughout his career he has had a particular interest in Fanconi anemia and his early work in this area culminated in the first clinical trial in which retroviral vectors were used for gene therapy of patients with Fanconi anemia group C. He is also actively developing gene therapies for hemophilia A and B. 

AB, Rutgers College

PhD, Bowman Gray School of Medicine

MD, Tulane University School of Medicine

Internship, Internal Medicine, University of North Carolina Hospitals GME

Residency, Internal Medicine, University of North Carolina Hospitals GME

Residency, Internal Medicine, National Cancer Institute, NIH

Fellowship, Hematology, National Cancer Institute, NIH

Certifications

American Board of Internal Medicine
61
Publications

Selected Publications

Safe and sustained overexpression of functional apolipoprotein a-i/high-density lipoprotein in apolipoprotein a-i-null mice by muscular adeno-associated viral serotype 8 vector gene transfer. Giovanni Cimmino, Wei Chen, Walter S. Speidl, Chiara Giannarelli, Borja Ibanez, Valentin Fuster, Roger Hajjar, Christopher E. Walsh, Juan J. Badimon. Journal of Cardiovascular Pharmacology

Chimeric AAV Cap sequences alter gene transduction. Peter Ward, Christopher E. Walsh. Virology

Factor VIII prophylaxis for adult patients with severe haemophilia A: Results of a US survey of attitudes and practices. Christopher E. Walsh, L. A. Valentino. Haemophilia

View All Publications

Annenberg Building Floor 24 Room 04A

1468 Madison Ave

New York, NY 10029

Annenberg Building Floor 24th Room 130E

1468 Madison Ave

New York, NY 10029

212-241-3443

Mount Sinai Doctors Floor 12th Floor Room Clinic Area

5 E 98th St

New York, NY 10029

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Walsh during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Gerson Lehrman Group
  • F. Hoffman-La Roche Ltd.
  • Novo Nordisk
  • CSL Behring
  • Biomarin Pharmaceutical
  • Guidepoint Global
  • Pfizer Inc., U.S. Pharmaceuticals Group
  • sanofi-aventis

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.